GLP-1 Therapies Are Changing What Samples Scientists Shop For
GLP-1 research is increasing the demand for well-characterized human biospecimens that represent multimorbid states.
Glucagon-like peptide-1 (GLP-1) therapies are changing more than what consumers add to their baskets in the supermarket; they’re changing what scientists shop for too.
Two decades after the approval of the first GLP-1 therapy for diabetes, additional benefits—both anticipated and unexpected—have come to light.
This has prompted investigation of metabolic medicines across a much broader range of indications. With this, there’s been a subtle shift in the biological samples researchers require to investigate potential risks and rewards.
“The research has moved beyond glucose-lowering and weight loss,” noted Dr. Brian Ogilvie, vice president of scientific consulting at BioIVT. “There is more evidence for cardiovascular and renal protection, efficacy in MASH [metabolic dysfunction-associated steatohepatitis], heart failure, obstructive sleep apnea, and other proposed indications.”
As potential indications of GLP-1 drugs expand, so do the mechanisms and routes of administration, with dual-agonists and oral options making their way to market.
Ogilvie spends his days advising drug developers on preclinical strategies and has observed changes in biospecimen requirements firsthand. He spoke with Technology Networks to explore how the rise of GLP-1 therapies has changed biospecimen shopping and which samples are needed to personalize obesity medicine.
As GLP-1 research has grown, so has the biospecimen shopping list
Many mechanistic studies use a case-control design; samples associated with one disease state are compared against healthy controls, with or without therapeutic exposure depending on the question being asked. But in GLP-1 research, the comparison to a single disease state might not provide the answer.
"These studies often require more than a single disease state or control sample," said Ogilvie.
“Researchers need specimens selected by variables such as BMI [body mass index], waist circumference, HbA1c [a measure of blood glucose control], lipid profile, diabetes status, renal and hepatic function, other comorbidities, medication exposure, and recent weight changes,” he continued.
Multimorbidity research may be conducted retrospectively, using existing biospecimens alongside the clinical records associated with those samples. Alternatively, in prospective studies, specimens and data are collected from participants across a given time course. Each type of research comes with its own challenges.
Challenges in obtaining and studying multimorbid specimens:
- As the number of disease characteristics that a specimen needs to meet increases, the pool of eligible patients or samples can decrease, making selection challenging.
- Researchers may obtain records from multiple datasets or recruit patients from different locations to overcome selection challenges. This can limit the reproducibility of research, as sample collection and storage conditions, among other factors, may differ between sites.
- As with all data, capturing information accurately is critical to reliable results. When multiple conditions are at play, the potential for missing data and inaccuracies can grow.
According to Ogilvie, matched samples, in which multiple materials or measurements come from the same donor, and longitudinal collections could be particularly valuable. These approaches enable researchers to distinguish a patient's baseline biology from changes associated with treatment.
Tissue type matters in GLP-1 studies
The type of samples researchers are interested in is also changing, which comes with its own considerations.
“[In GLP-1 research,] the relevant materials may extend across tissues, including plasma or serum, PBMCs [peripheral blood mononuclear cells], subcutaneous and visceral adipose tissue, liver, skeletal muscle, pancreatic tissue, and primary cells derived from these tissues,” Ogilvie commented.
He highlighted that studying adipose tissue (body fat) presents additional challenges. "Visceral and subcutaneous adipose tissue are not interchangeable, and collection conditions can influence results."
The differences in function between human subcutaneous adipocytes, the fat cells just beneath the skin, and visceral adipocytes, the fat cells surrounding organs, have been clear for some time. In 2025, researchers produced an atlas containing tens of thousands of adipocyte nuclei across both adipose tissue types. Although cell populations were similar, differences in cell subtypes and communication patterns were evident.
Understanding changes to adipose tissue is essential in GLP-1 research. Studies have investigated GLP-1 receptor mRNA expression in fat samples, adipose remodeling, and fat browning following GLP-1 agonism.
Therefore, acknowledging the differences between tissue types and understanding how these differences may influence results is key when selecting biospecimens and interpreting findings.
Challenges in biospecimen selection:
- Adequate data collection and/or patient recruitment can pose challenges in multimorbidity research.
- Extensive metabolic, clinical, and treatment information is required to study multimorbid specimens.
- As the type of tissue being studied changes, differences between specific tissue types need to be acknowledged.
Turning variability into valuable insights in GLP-1 research
Human biological variability is a challenge across experimental research. But with appropriate annotation, variability can become a source of useful information.
"Well-annotated biospecimens enable researchers to connect molecular and cellular findings to the biology of specific patient populations rather than viewing human variability as experimental noise." — Dr. Brian Ogilvie.
The more complex the condition is, the more important it is to disentangle the noise. This is particularly true when the end goal is personalized obesity medicine, as small signals can help scientists understand why treatment outcomes vary from person to person.
“Clinical variables such as glycemic control, body composition, disease stage, comorbidities, and medication history can be used to distinguish broad disease-associated signals from those observed only within specific patient populations,” commented Ogilvie.
“This is particularly valuable for understanding disease mechanisms, identifying responder and non-responder biology, evaluating whether a therapeutic target is relevant across metabolically important tissues such as adipose tissue, liver, skeletal muscle, and immune cells, and selecting biomarkers that may translate into clinical studies.”
Well-annotated specimens could help researchers:
- Separate broad disease signals from patterns associated with specific patient populations.
- Investigate why some patients respond differently from others, supporting the development of personalized metabolic medicines.
- Assess targets across multiple metabolically relevant tissues and identify biomarkers with potential clinical relevance.
Paving the way for personalized obesity medicine
With the growing use of GLP-1 therapies comes a growing set of questions.
"We still do not have a full understanding of why patients differ in weight loss, glycemic response, tolerability, and durability, or how to select the best agent for an individual patient," said Ogilvie.
He highlighted even more unknowns: Do patients need to remain on treatment long term? What happens after dose reduction? Are the benefits maintained?
Although scientists are already reaching for different sample types to answer these questions, Ogilvie highlighted several other areas that require attention. “Body composition needs more precise study to preserve skeletal muscle, strength, and physical function.
“It will also be important to determine which cardiovascular, renal, hepatic, inflammatory, or neurological effects are direct consequences of receptor pharmacology, and which are secondary to weight loss.”
Answering questions at that level of specificity requires experiments designed around the biology that researchers are trying to understand. A recent study used mouse models to map the brain signaling pathways through which semaglutide drives weight loss. While these models can reveal valuable mechanistic insights, determining whether they explain variable patient responses requires studies in relevant human samples.
That puts human biospecimens at the center of where GLP-1 research goes next.
Understanding variable GLP-1 responses:
- Determining whether wider effects of GLP-1 therapies result directly from receptor pharmacology or indirectly from weight loss will require specific mechanistic studies in human samples.
- Translating findings from experimental models to patients will require relevant, well-characterized human biospecimens, which will likely be more complex samples to represent metabolic conditions.
Better biospecimens will help scientists understand GLP-1s
Defining the many mechanisms of GLP-1 therapies will be crucial for understanding why outcomes vary among patients, and what causes the range of seemingly beneficial—as well as unwanted—effects.
This is particularly true in multimorbid disease research, where overlapping conditions and medications can influence biological signals.
As the questions surrounding GLP-1 therapies become more specific, scientists will require biospecimens that meet stringent criteria in order to answer them.
Key takeaways
- An increasing number of potential indications has created more complex questions in GLP-1 therapy research.
- Reliable multimorbidity research relies on detailed clinical annotation, appropriate tissue selection, and consistent sample handling.
- Better-characterized biospecimens could help researchers investigate the wider effects of GLP-1s, explore treatment responses, validate targets, and identify biomarkers.